Based on the notion that potent HSF1 inhibitors have been discovered and developed, the present data suggest that HSF1 might represent a valuable, druggable target in human HCC subsets characterized by the activation of the c-Myc protooncogene. The gene discussed is MYC; the disease is hepatocellular carcinoma.